A novel migraine prevention drug developed by Neuralis Therapeutics has received FDA fast-track designation after Phase II trials demonstrated a 70 percent reduction in monthly migraine days for chronic sufferers. The oral medication targets a newly identified neural pathway.
Unlike existing CGRP inhibitors, the drug works on glutamate signaling and has shown fewer side effects in clinical trials. Patients reported minimal fatigue and no cardiovascular concerns during the 24-week study period.
If approved, the medication could reach the market by early 2027, offering an alternative for the estimated 39 million Americans who suffer from migraines and have not responded adequately to current treatments.
